Leerink: Altimmune an Attractive Opportunity in MASH Therapy
Altimmune (NASDAQ:ALT) has garnered considerable attention from analysts, who view it as a promising investment in the evolving landscape of MASH therapeutics. The company's lead drug candidate, pemvidutide, a dual GLP-1/glucagon receptor agonist, has demonstrated encouraging results in clinical trials, particularly in addressing metabolic dysfunction-associated steatohepatitis (MASH). This positive outlook is fueled by compelling clinical data and a strong vote of confidence from financial institutions, positioning Altimmune as a noteworthy player in the biopharmaceutical sector for liver and metabolic health.
Leerink analyst Thomas Smith recently initiated coverage of Altimmune (NASDAQ:ALT) with an 'Outperform' rating and a $10 price target. This endorsement underscores the growing conviction in the company's potential, especially within the MASH treatment arena. Smith highlighted pemvidutide's distinctive dual-agonist profile and its capacity for broader application in related liver conditions, including those associated with alcohol use, as key differentiators.
This optimistic analyst coverage closely followed the announcement of 48-week outcomes from Altimmune's IMPACT Phase 2b trial in May. The trial rigorously evaluated pemvidutide in patients afflicted with MASH. The findings revealed that the drug significantly improved various cardiometabolic indicators when compared to a placebo. Specifically, participants receiving the 1.8 mg dose experienced notable reductions in triglycerides and total cholesterol levels, alongside sustained weight reduction, decreased body mass index, a smaller waist circumference, and improvements in both systolic and diastolic blood pressure readings. These comprehensive improvements underscore pemvidutide's multifaceted benefits beyond just liver health.
Further reinforcing the drug's safety and efficacy profile, the results, presented at the European Association for the Study of the Liver Congress 2026 in Barcelona, indicated that pemvidutide was generally well-tolerated over the 48-week duration. A minimal number of patients discontinued treatment due to adverse events, signifying a favorable safety profile. Prior data had already highlighted substantial improvements in liver fibrosis and stiffness among patients treated with pemvidutide compared to the placebo group, further solidifying its therapeutic potential.
Altimmune, a clinical-stage biopharmaceutical company, specializes in the development of pemvidutide for various metabolic and liver disorders. The cumulative evidence from clinical trials and the strong analyst backing suggest a bright future for the company, making it a compelling consideration for those interested in the biopharma space and the burgeoning field of MASH treatments.
